Selegiline for levodopa-induced motor complications in Parkinson's disease

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To compare selegiline to placebo for managing levodopa-related complications. We will test the following hypotheses: 1) patients receiving selegiline will have improvement in their wearing-off symptoms. 2) patients receiving selegiline will experience new-onset or worsening peak-dose dyskinesias. 3) patients receiving selegiline can have their total daily LD dosage reduced.